UNSPSC 51191505: Ethacrynate sodium

This classification denotes a loop diuretic with the molecular formula C13H11Cl2O4.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K41MYV7MPM, chemically known as sodium (2,3-dichloro-4-(2-methylenebutyryl)phenoxy)acetate but generally known as ethacrynate sodium, which bears US NIH Compound Identifier 23003. As of Q4 2014, ETHACRYNATE SODIUM remains the US FDA Preferred Term for this commodity. Ethacrynate sodium bears US NLM identifiers UMLS ID C0014962 and NCI Concept Code C47993.

SMILES: CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)[O-])CL)CL.[NA+].

UNSPSC 51191505 Ethacrynate sodium (Commodity) represents pharmaceutical and chemical products purchased by state and local government entities for medical and operational use, though recent solicitations under this code span both pharmaceutical supply agreements and water treatment chemicals, indicating potential classification overlap or broad categorical application. State and local governments procure these products through direct municipal purchasing and cooperative multistate agreements; the issuing bodies include municipal public works departments managing water treatment operations and statewide procurement alliances administering pharmaceutical supply contracts across multiple jurisdictions. The City of Meriden and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the primary recent buyer categories—municipal utilities handling chemical procurement and coordinated multistate health systems requiring pharmaceutical sourcing through established wholesaler networks.

Recent activity spans Connecticut and Minnesota. The City of Meriden posted an IFB for sodium bisulfite chemical supply (solicitation B02715, due July 29, 2026) to support its Water Pollution Control Facility's treatment operations, with pricing evaluated on a unit-cost basis and performance bonds required. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and over-the-counter products distributed across participating state and local facilities in Minnesota and Oregon, with vendor selection weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and 15 percent on administrative and capability factors. Awarded MMCAP vendors must maintain relationships with three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health 110 and 112, and Morris & Dickson Co.) and comply with current Good Manufacturing Practices and Drug Supply Chain Security Act standards. The MMCAP contract term runs two years for new vendors with optional extensions, while incumbent amendments align with existing expirations through June 30, 2028.